Long-peptide cross-presentation by human dendritic cells occurs in vacuoles by peptide exchange on nascent MHC class i molecules

Journal of Immunology

Volumn 196, Issue 4, 2016, Pages 1711-1720

  Ma, Wenbin ^a,b,c   Zhang, Yi ^a,b,d   Vigneron, Nathalie ^a,b,c   Stroobant, Vincent ^a,c   Thielemans, Kris ^e   Van Der Bruggen, Pierre ^a,b,c   Van Den Eynde, Benoît J ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b Walloon Excellence in Life Sciences and Biotechnology (Welbio)   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOCYTE PROTEIN PMEL 17; PROTEIN SEC22B; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; PEPTIDE; PROTEASOME;

ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CELL VACUOLE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; CELL CULTURE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY;

ANTIGEN PRESENTATION; CELL LINE; CELLS, CULTURED; CROSS-PRIMING; DENDRITIC CELLS; GP100 MELANOMA ANTIGEN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; T-LYMPHOCYTES, CYTOTOXIC; VACUOLES;

EID: 84958534238     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501574     Document Type: Article

References (50)

1. Ackerman, A. L., and P. Cresswell. 2004. Cellular mechanisms governing crosspresentation of exogenous antigens. Nat. Immunol. 5: 678-684.
2. Joffre, O. P., E. Segura, A. Savina, and S. Amigorena. 2012. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12: 557-569.
3. Wagner, C. S., J. E. Grotzke, and P. Cresswell. 2012. Intracellular events regulating cross-presentation. Front. Immunol. 3: 138.
4. Melief, C. J., and S. H. van der Burg. 2008. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8: 351-360.
5. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, R. Offringa, and S. H. van der Burg. 2007. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179: 5033-5040.
6. Vambutas, A., J. DeVoti, M. Nouri, J. W. Drijfhout, G. B. Lipford, V. R. Bonagura, S. H. van der Burg, and C. J. M. Melief. 2005. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23: 5271-5280.
7. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
8. Ménager, J., F. Ebstein, R. Oger, P. Hulin, S. Nedellec, E. Duverger, A. Lehmann, P. M. Kloetzel, F. Jotereau, and Y. Guilloux. 2014. Crosspresentation of synthetic long peptides by human dendritic cells: A process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLoS One 9: e89897.
9. Segura, E., M. Durand, and S. Amigorena. 2013. Similar antigen crosspresentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J. Exp. Med. 210: 1035-1047.
10. Faure, F., A. Mantegazza, C. Sadaka, C. Sedlik, F. Jotereau, and S. Amigorena. 2009. Long-lasting cross-presentation of tumor antigen in human DC. Eur. J. Immunol. 39: 380-390.
11. Rosalia, R. A., E. D. Quakkelaar, A. Redeker, S. Khan, M. Camps, J. W. Drijfhout, A. L. Silva, W. Jiskoot, T. van Hall, P. A. van Veelen, et al. 2013. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur. J. Immunol. 43: 2554-2565.
12. Cebrian, I., G. Visentin, N. Blanchard, M. Jouve, A. Bobard, C. Moita, J. Enninga, L. F. Moita, S. Amigorena, and A. Savina. 2011. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell 147: 1355-1368.
13. Basha, G., K. Omilusik, A. Chavez-Steenbock, A. T. Reinicke, N. Lack, K. B. Choi, and W. A. Jefferies. 2012. A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat. Immunol. 13: 237-245.
14. Zehner, M., A. L. Marschall, E. Bos, J. G. Schloetel, C. Kreer, D. Fehrenschild, A. Limmer, F. Ossendorp, T. Lang, A. J. Koster, et al. 2015. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells. Immunity 42: 850-863.
15. Basha, G., G. Lizée, A. T. Reinicke, R. P. Seipp, K. D. Omilusik, and W. A. Jefferies. 2008. MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells. PLoS One 3: e3247.
16. Grommé, M., F. G. Uytdehaag, H. Janssen, J. Calafat, R. S. van Binnendijk, M. J. Kenter, A. Tulp, D. Verwoerd, and J. Neefjes. 1999. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl. Acad. Sci. USA 96: 10326-10331.
17. Song, R., and C. V. Harding. 1996. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J. Immunol. 156: 4182-4190.
18. Zou, L., J. Zhou, J. Zhang, J. Li, N. Liu, L. Chai, N. Li, T. Liu, L. Li, Z. Xie, et al. 2009. The GTPase Rab3b/3c-positive recycling vesicles are involved in crosspresentation in dendritic cells. Proc. Natl. Acad. Sci. USA 106: 15801-15806.
19. MacAry, P. A., M. Lindsay, M. A. Scott, J. I. Craig, J. P. Luzio, and P. J. Lehner. 2001. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells. Proc. Natl. Acad. Sci. USA 98: 3982-3987.
20. Germeau, C., W. Ma, F. Schiavetti, C. Lurquin, E. Henry, N. Vigneron, F. Brasseur, B. Lethé, E. De Plaen, T. Velu, et al. 2005. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201: 241-248.
21. Morel, S., F. Lévy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper,A.-L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.-C. Cerottini, T. Boon, et al. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12: 107-117.
22. Parmentier, N., V. Stroobant, D. Colau, P. de Diesbach, S. Morel, J. Chapiro, P. van Endert, and B. J. Van den Eynde. 2010. Production of an antigenic peptide by insulin-degrading enzyme. Nat. Immunol. 11: 449-454.
23. Berger, G., S. Durand, C. Goujon, X. N. Nguyen, S. Cordeil, J. L. Darlix, and A. Cimarelli. 2011. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat. Protoc. 6: 806-816.
24. Marks, M. S., J. S. Blum, and P. Cresswell. 1990. Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens. J. Cell Biol. 111: 839-855.
25. Holtkamp, S., S. Kreiter, A. Selmi, P. Simon, M. Koslowski, C. Huber, O. Tureci, and U. Sahin. 2006. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108: 4009-4017.
26. Bonehill, A., C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. Van Der Bruggen, and K. Thielemans. 2004. Messenger RNAelectroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 172: 6649-6657.
27. Follenzi, A., L. E. Ailles, S. Bakovic, M. Geuna, and L. Naldini. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25: 217-222.
28. Shaw-Jackson, C., and T. Michiels. 1999. Absence of internal ribosome entry site-mediated tissue specificity in the translation of a bicistronic transgene. J. Virol. 73: 2729-2738.
29. Salter, R. D., D. N. Howell, and P. Cresswell. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21: 235-246.
30. Baas, E. J., H. M. van Santen, M. J. Kleijmeer, H. J. Geuze, P. J. Peters, and H. L. Ploegh. 1992. Peptide-induced stabilization and intracellular localization of empty HLA class I complexes. J. Exp. Med. 176: 147-156.
31. De Silva, A. D., A. Boesteanu, R. Song, N. Nagy, E. Harhaj, C. V. Harding, and S. Joyce. 1999. Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by lowaffinity peptides. J. Immunol. 163: 4413-4420.
32. Leonhardt, R. M., K. Keusekotten, C. Bekpen, and M. R. Knittler. 2005. Critical role for the tapasin-docking site of TAP2 in the functional integrity of the MHC class I-peptide-loading complex. J. Immunol. 175: 5104-5114.
33. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443-446.
34. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930.
35. Hammer, G. E., F. Gonzalez, M. Champsaur, D. Cado, and N. Shastri. 2006. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat. Immunol. 7: 103-112.
36. Bacik, I., J. H. Cox, R. Anderson, J. W. Yewdell, and J. R. Bennink. 1994. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino-but not carboxyl-terminus of the peptide. J. Immunol. 152: 381-387.
37. Weinzierl, A. O., D. Rudolf, N. Hillen, S. Tenzer, P. van Endert, H. Schild, H. G. Rammensee, and S. Stevanović. 2008. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur. J. Immunol. 38: 1503-1510.
38. Baravalle, G., D. Schober, M. Huber, N. Bayer, R. F. Murphy, and R. Fuchs. 2005. Transferrin recycling and dextran transport to lysosomes is differentially affected by bafilomycin, nocodazole, and low temperature. Cell Tissue Res. 320: 99-113.
39. Knorr, R., C. Karacsonyi, and R. Lindner. 2009. Endocytosis of MHC molecules by distinct membrane rafts. J. Cell Sci. 122: 1584-1594.
40. Kirchhausen, T. 2000. Clathrin. Annu. Rev. Biochem. 69: 699-727.
41. Tomoda, H., Y. Kishimoto, and Y. C. Lee. 1989. Temperature effect on endocytosis and exocytosis by rabbit alveolar macrophages. J. Biol. Chem. 264: 15445-15450.
42. Allaire, P. D., A. L. Marat, C. Dall'Armi, G. Di Paolo, P. S. McPherson, and B. Ritter. 2010. The Connecdenn DENN domain: A GEF for Rab35 mediating cargo-specific exit from early endosomes. Mol. Cell 37: 370-382.
43. Kouranti, I., M. Sachse, N. Arouche, B. Goud, and A. Echard. 2006. Rab35 regulates an endocytic recycling pathway essential for the terminal steps of cytokinesis. Curr. Biol. 16: 1719-1725.
44. Brand, M., E. Jansen, and H. L. Ploegh. 1985. Effect of reduced temperature on glycoprotein (Ig, HLA) processing and transport in lymphoid cells. Mol. Immunol. 22: 787-794.
45. Braulke, T., A. Hasilik, and K. von Figura. 1988. Low temperature blocks transport and sorting of cathepsin D in fibroblasts. Biol. Chem. Hoppe Seyler 369: 441-449.
46. Rivoltini, L., P. Squarcina, D. J. Loftus, C. Castelli, P. Tarsini, A. Mazzocchi, F. Rini, V. Viggiano, F. Belli, and G. Parmiani. 1999. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 59: 301-306.
47. Valmori, D., J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar, D. Liénard, D. Rimoldi, V. Cerundolo, F. Jotereau, J. C. Cerottini, et al. 1999. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int. Immunol. 11: 1971-1980.
48. Chapatte, L., M. Ayyoub, S. Morel, A. L. Peitrequin, N. Lévy, C. Servis, B. J. Van den Eynde, D. Valmori, and F. Lévy. 2006. Processing of tumorassociated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res. 66: 5461-5468.
49. Dannull, J., D. T. Lesher, R. Holzknecht, W. Qi, G. Hanna, H. Seigler, D. S. Tyler, and S. K. Pruitt. 2007. Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood 110: 4341-4350.
50. Guillaume, B., V. Stroobant, M. P. Bousquet-Dubouch, D. Colau, J. Chapiro, N. Parmentier, A. Dalet, and B. J. Van den Eynde. 2012. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J. Immunol. 189: 3538-3547.